

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	3017267
<b>Application Number:</b>	09831180
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	1189
<b>Title of Invention:</b>	Novel trypsin family serine proteases
<b>First Named Inventor/Applicant Name:</b>	Chiaki Senoo
<b>Customer Number:</b>	21559
<b>Filer:</b>	James D. DeCamp/Sarah Wilcox
<b>Filer Authorized By:</b>	James D. DeCamp
<b>Attorney Docket Number:</b>	50026/027001
<b>Receipt Date:</b>	18-MAR-2008
<b>Filing Date:</b>	03-AUG-2001
<b>Time Stamp:</b>	17:20:53
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	2515
Deposit Account	032095
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1		50026_027001_supplemental_IDS_and_1449.pdf	98404 82e24e28289272b48f7342d3a2309194b3544e6d	yes	3
<b>Multipart Description/PDF files in .zip description</b>					
	<b>Document Description</b>		<b>Start</b>		<b>End</b>
	Information Disclosure Statement Letter		1		2
	Information Disclosure Statement (IDS) Filed		3		3
<b>Warnings:</b>					
<b>Information:</b>					
2	Foreign Reference	50026_027001_WO98036054.pdf	5971343 03cd95514bf95352b9e98a9b2b063a70c4e6f5f	no	168
<b>Warnings:</b>					
<b>Information:</b>					
3	NPL Documents	50026_027001_EESR_for_07023493_5.pdf	259565 22a14c15957c00c18a5f5ace430d85edf49c7854	no	8
<b>Warnings:</b>					
<b>Information:</b>					
4	NPL Documents	50026_027001_EESR_for_07023492_7.pdf	294194 d7e82a37c613666ca8a9d9ddc78d9dcdf0285ea3	no	9
<b>Warnings:</b>					
<b>Information:</b>					
5	NPL Documents	50026_027001_Lum_and_Biobel_Developmental_Biology_1997.pdf	2013708 87a1492a990a0445ee1526091363a120243080a	no	15
<b>Warnings:</b>					
<b>Information:</b>					
6	Miscellaneous Incoming Letter	50026_027001_Communication_re_IDS_copy_of_IDS_1449_and_postcard.pdf	220084 85cd896fe3364ac10137865310b3a3fc55b71c2	no	6
<b>Warnings:</b>					
<b>Information:</b>					

7	NPL Documents	50026_027001_Chung_et_al_Biochemistry_1986.pdf	1020227 83330dc0bc1a444061e7db1be6af1d382a45a33f1	no	8
<b>Warnings:</b>					
<b>Information:</b>					
8	NPL Documents	50026_027001_McMullen_et_al_Biochemistry_1991.pdf	859305 48e597e9c3e047b200ba1ac181db0469830564919	no	7
<b>Warnings:</b>					
<b>Information:</b>					
9	NPL Documents	50026_027001_EMBL_AA781356_1998.pdf	104023 3553473da0c0b5d8606d2dc2b70428ee2a0f0ca3	no	2
<b>Warnings:</b>					
<b>Information:</b>					
10	NPL Documents	50026_027001_Liu_et_al_cancer_research_1996.pdf	1351717 2b26eb7966a9113d94571b60314e5405a309a7e1	no	9
<b>Warnings:</b>					
<b>Information:</b>					
11	NPL Documents	50026_027001_Peehl_Cancer_Supplement_1995.pdf	709977 c42a8be615946d3b2ce552e7b057bd55021dc1e	no	6
<b>Warnings:</b>					
<b>Information:</b>					
12	NPL Documents	50026_027001_EMBL_AA436049_1997.pdf	78715 54963f56e0d06a50f5e03dc16187577991c4	no	1
<b>Warnings:</b>					
<b>Information:</b>					
13	NPL Documents	50026_027001_Poorafshar_et_al_Eur_J_Biochem_1999.pdf	1068077 cd7e4b84d135b0cd819413b0a890afabf70f1	no	7
<b>Warnings:</b>					
<b>Information:</b>					
14	NPL Documents	50026_027001_Yamashiro_et_al_biochimica_et_biophys_acta_1997.pdf	344201 319b615ad3540e2314a126262a208946d83c2926	no	4
<b>Warnings:</b>					
<b>Information:</b>					
15	Fee Worksheet (PTO-06)	fee-info.pdf	8184 296780c8da03dc05e3b3e7ad38e07b2a2c796052	no	2
<b>Warnings:</b>					
<b>Information:</b>					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

**New Applications Under 35 U.S.C. 111**

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

**National Stage of an International Application under 35 U.S.C. 371**

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

**New International Application Filed with the USPTO as a Receiving Office**

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.